Our studies indicate that appropriately designed tumor specific nitric oxide donors may be useful in the clinic for treating human tumors that overexpress ABC transporters (including cancer stem cells) or in other diseases where drug resistance may result from the presence of ATP-dependent efflux proteins. Here, ABCG2 is linked to neoplasm.